Skip To Main Content

Our Oncology Portfolio

Find product and prescribing information, as well as other resources, for Genentech’s oncology portfolio below.

A

Alecensa®

(alectinib)

View Product Page

Avastin®

(bevacizumab)

Prescribing Information

Safety Data Sheets:

AVASTIN® Vials (100 mg)
AVASTIN® Vials (400 mg)

Healthcare Provider Letters:

Important Drug Warning: Necrotizing Fasciitis - Apr 2013
Warning for Counterfeit Product Labeled as Avastin in the United States Feb 2012
Important Change to Avastin® label for treatment of metastatic breast cancer - Nov 2011
Important New Safety Information in Women Receiving AVASTIN - Oct 2011
Intraocular Inflammatory Reactions - Dec 2008
Microangiopathic Hemolytic Anemia (MAHA) - July 2008
Tracheoesophageal (TE) Fistula - April 2007
Cases of RPLS in Patients Receiving AVASTIN - Sept 2006
VEGF antibodies for the treatment of retinopathy of prematurity - Aug 2006

C

Columvi™

(glofitamab-gxbm)

View Product Page

Cotellic®

(cobimetinib)

Prescribing Information
Important Patient Information

Safety Data Sheets:

COTELLIC Tablets (20 mg)

E

Erivedge®

(vismodegib)

Prescribing Information
Medication Guide

Safety Data Sheets:

ERIVEDGE® Capsules (150 mg)

Healthcare Provider Letters:

Important Drug Warning - November 2016
Serious Risk with Use of Erivedge (vismodegib) Capsules: Premature Epiphyseal Fusion - June 2016
Extension of Pregnancy Prevention Duration for Women of Childbearing Potential and Waiting Periods for Blood Donations and Lactation in Patients taking ERIVEDGE (vismodegib) capsule - February 2016

G

Gazyva®

(obinutuzumab)

Prescribing Information

Safety Data Sheets:

GAZYVA® Vials (1000 mg/40 mL)

Healthcare Provider Letter:

Gazyva™ (obinutuzumab) Important Drug Warning: Thrombocytopenia - Feb 2014

H

Herceptin®

(trastuzumab)

Prescribing Information

Safety Data Sheets:

HERCEPTIN® Vials (150 mg)

Healthcare Provider Letters:

440mg Vials and Herceptin BWFI Diluent - June 2008
Updated Cardiotoxicity Information - Aug 2005
Fatal Embryo-Fetal Toxicity due to Herceptin Exposure During Pregnancy

Herceptin Hylecta™

(trastuzumab and hyaluronidase-oysk)

Prescribing Information

Safety Data Sheets:

HERCEPTIN HYLECTA™ Vials (600 mg/5 mL)

I

Itovebi™

(inavolisib)

View Product Page

K

Kadcyla®

(ado-trastuzumab emtansine)

Prescribing Information

Safety Data Sheets:

KADCYLA® Lyophilized Powder in Vials (100 mg)
KADCYLA® Lyophilized Powder in Vials (160 mg)
KADCYLA® Solution

Healthcare Provider Letters:

Kadcyla Important Safety Warning: Hemorrhage - Nov 2013
KADCYLA (ado-trastuzumab emtansine) error on the carton - May 2013

L

Lunsumio™

(mosunetuzumab-axgb)

View Product Page

P

Perjeta®

(pertuzumab)

Prescribing Information

Safety Data Sheets:

PERJETA® (420 mg)

Phesgo®

(pertuzumab, trastuzumab, and hyaluronidase-zzxf)

Prescribing Information

Safety Data Sheets:

PHESGO® (pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (60 mg/mL, 60 mg/mL)
PHESGO® (pertuzumab, trastuzumab & hyaluronidase-zzxf) Injection (80 mg/mL, 40 mg/mL)

Polivy®

(polatuzumab vedotin-piiq)

View Product Page

R

Rituxan®

(rituximab)

Prescribing Information
Medication Guide

Safety Data Sheets:

RITUXAN® Vials (100 mg/10 mL)
RITUXAN® Vials (500 mg/50 mL)

Healthcare Provider Letters:

Rituxan® (rituximab) Label: Hepatitis B Reactivation - October 2013
Important Drug Warning: Updated Safety Information - Dec 2006
Important Drug Warning: New Safety Information - Sept 2008
Important Drug Warning: Updated Safety Information - Oct 2009

Rituxan Hycela®

(rituximab and hyaluronidase human)

Prescribing Information
Medication Guide

Safety Data Sheets:

RITUXAN HYCELA® Vials (1600 mg)
RITUXAN HYCELA® Vials (1400 mg)

Rozlytrek®

(entrectinib)

Prescribing Information
Important Patient Information

Safety Data Sheets:

ROZLYTREK® Capsules (100 mg)
ROZLYTREK® Capsules (200 mg)

T

Tarceva®

(erlotinib)

Prescribing Information

Safety Data Sheets:

TARCEVA® Tablets (25 mg)
TARCEVA® Tablets (100 mg)
TARCEVA® Tablets (150 mg)

Healthcare Provider Letters:

Important Prescribing Information - October 2016
Important Correction of Drug Information - June 2016

Tecentriq®

(atezolizumab)

View Product Page

Tecentriq Hybreza™

(atezolizumab and hyaluronidase-tqjs)

View Product Page

V

Venclexta®

(venetoclax)

View Product Page

X

Xeloda®

(capecitabine)

Prescribing Information
Important Patient Information

Safety Data Sheets:

XELODA® Tablets (150 mg)
XELODA® Tablets (500 mg)

Z

Zelboraf®

(vemurafenib)

Prescribing Information
Medication Guide

Safety Data Sheets:

ZELBORAF® F.C. Tablets (240 mg)

Healthcare Provider Letters:

Important Drug Warning - June 2017
Important Drug Warning - March 2014
Important Drug Warning - August 2013
Publications icon

Publications

Visit PubMed.gov to view scientific literature for Genentech oncology portfolio products.

Avastin® at PubMed.gov

Cotellic® at PubMed.gov

Erivedge® at PubMed.gov

Gazyva® at PubMed.gov

Herceptin® at PubMed.gov

Kadcyla® at PubMed.gov

Perjeta® at PubMed.gov

Phesgo® at PubMed.gov

Rituxan® at PubMed.gov

Rozlytrek® at PubMed.gov

Xeloda® at PubMed.gov

Zelboraf® at PubMed.gov

Scientific congresses icon

Scientific Congresses

Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at Medically.gene.com.

Clinical trials icon

Clinical Trials

Find information about active clinical research for Genentech oncology portfolio products.

Avastin® at ClinicalTrials.gov

Cotellic® at ClinicalTrials.gov

Erivedge® at ClinicalTrials.gov

Gazyva® at ClinicalTrials.gov

Herceptin® at ClinicalTrials.gov

Kadcyla® at ClinicalTrials.gov

Perjeta® at ClinicalTrials.gov

Phesgo® at ClinicalTrials.gov

Rituxan® at ClinicalTrials.gov

Rozlytrek® at ClinicalTrials.gov

Xeloda® at ClinicalTrials.gov

Zelboraf® at ClinicalTrials.gov

Additional resources icon

Additional Resources

Connect with a Medical Science Liaison

Browse the Genentech Medical Information Library